Guggenheim Lowers Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $40.00

Unicycive Therapeutics (NASDAQ:UNCY) had its price objective lowered by Guggenheim from $46.00 to $40.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s target price indicates a potential upside of 477.20% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Friday, March 27th. Westpark Capital assumed coverage on Unicycive Therapeutics in a research report on Thursday, February 19th. They issued a “buy” rating for the company. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $27.67.

Unicycive Therapeutics Price Performance

Shares of NASDAQ:UNCY opened at $6.93 on Thursday. The business has a fifty day moving average price of $6.67 and a 200-day moving average price of $5.81. The company has a market capitalization of $174.91 million, a PE ratio of -3.19 and a beta of 1.81. Unicycive Therapeutics has a 1-year low of $3.71 and a 1-year high of $11.00.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.36). On average, sell-side analysts anticipate that Unicycive Therapeutics will post -0.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Lazard Asset Management LLC bought a new position in Unicycive Therapeutics in the second quarter worth about $55,000. JPMorgan Chase & Co. increased its holdings in shares of Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after purchasing an additional 21,525 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Unicycive Therapeutics during the third quarter worth about $182,000. Quadrature Capital Ltd acquired a new stake in Unicycive Therapeutics during the 4th quarter valued at approximately $226,000. Finally, State Street Corp boosted its position in Unicycive Therapeutics by 19.0% in the 4th quarter. State Street Corp now owns 65,227 shares of the company’s stock worth $376,000 after purchasing an additional 10,400 shares in the last quarter. 40.42% of the stock is owned by institutional investors.

More Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Piper Sandler reaffirmed a Buy on Unicycive, maintaining analyst support that can sustain demand among growth/biotech investors. Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)
• Positive Sentiment: Guggenheim kept a Buy rating and a high $40 price target (down from $46), signaling continued bullish conviction and large upside vs. the current share price — a support for longer‑term investors. Benzinga
• Positive Sentiment: Coverage from Noble Financial includes a reportedly positive Q3 outlook and modest intraquarter upward tweaks, which may limit downside for near‑term earnings expectations. Noble Financial Has Positive Forecast for UNCY Q3 Earnings
• Neutral Sentiment: Noble Financial made small upward revisions to certain near‑term quarters (Q1 and a slight Q2 tweak), but also trimmed its FY2026 outlook — a mixed signal that tempers how much the stock should move on those changes alone.
• Negative Sentiment: HC Wainwright issued broad downgrades across Q2–Q4 2026 and materially cut FY2026–FY2030 EPS forecasts (FY2026 from ~($0.94) to ($1.67); FY2028–FY2030 reductions are especially large). Those cuts imply slower near‑term profitability and push out the path to the previously modeled upside, which is likely the main driver of downward pressure on the share price.
• Negative Sentiment: Noble also lowered its Q4 2026 and FY2026 numbers in the same reporting window, which adds further downward bias to consensus near‑term earnings expectations.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.